Publications
2021
Scholarly publications
Noort, S., Wander, P., Alonzo, T. A., Smith, J., Ries, R. E., Gerbing, R. B., Dolman, M. E. M., Locatelli, F., Reinhardt, D., Baruchel, A., Stary, J., Molenaar, J. J., Stam, R. W., van den Heuvel-Eibrink, M. M., Zwaan, M. C., & Meshinchi, S. (2021). The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. Haematologica, 106(2), 630-634. https://doi.org/10.3324/haematol.2019.236745
Schubert, N. A., Schild, L., van Oirschot, S., Keller, K. M., Alles, L. K., Vernooij, L., Nulle, M. E., Dolman, M. E. M., van den Boogaard, M. L., & Molenaar, J. J. (2021). Combined targeting of the p53 and pRb pathway in neuroblastoma does not lead to synergistic responses. European Journal of Cancer, 142, 1-9. https://doi.org/10.1016/j.ejca.2020.10.009
Wienke, J., Dierselhuis, M. P., Tytgat, G. A. M., Künkele, A., Nierkens, S., & Molenaar, J. J. (2021). The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology. European Journal of Cancer, 144, 123-150. https://doi.org/10.1016/j.ejca.2020.11.014
Kildisiute, G., Kholosy, W. M., Young, M. D., Roberts, K., Elmentaite, R., van Hooff, S. R., Pacyna, C. N., Khabirova, E., Piapi, A., Thevanesan, C., Bugallo-Blanco, E., Burke, C., Mamanova, L., Keller, K. M., Langenberg-Ververgaert, K. P. S., Lijnzaad, P., Margaritis, T., Holstege, F. C. P., Tas, M. L., ... Behjati, S. (2021). Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. Science advances, 7(6). https://doi.org/10.1126/sciadv.abd3311
Wander, P., Arentsen-Peters, S. T. C. J. M., Pinhanҫos, S. S., Koopmans, B., Dolman, M. E. M., Ariese, R., Bos, F. L., Castro, P. G., Jones, L., Schneider, P., Navarro, M. G., Molenaar, J. J., Rios, A. C., Zwaan, C. M., & Stam, R. W. (2021). High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia. Translational Oncology, 14(5), 101048. https://doi.org/10.1016/j.tranon.2021.101048
Vernooij, L., Bate-Eya, L. T., Alles, L. K., Lee, J. Y., Koopmans, B., Jonus, H. C., Schubert, N. A., Schild, L., Lelieveld, D., Egan, D. A., Kerstjens, M., Stam, R. W., Koster, J., Goldsmith, K. C., Molenaar, J. J., & Dolman, M. E. M. (2021). High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.MCT-20-0666
Tas, M. L., Molenaar, J. J., Peek, A. M. L., Lequin, M. H., Verdijk, R. M., de Krijger, R. R., Tytgat, G. A. M., & van Noesel, M. M. (2021). Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort. Journal of Pediatric Hematology/Oncology. https://doi.org/10.1097/MPH.0000000000002067
2020
Scholarly publications
Tas, M. L., Nagtegaal, M., Kraal, K. C. J. M., Tytgat, G. A. M., Abeling, N. G. G. M., Koster, J., Pluijm, S. M. F., Zwaan, C. M., de Keizer, B., Molenaar, J. J., & van Noesel, M. M. (2020). Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease. Pediatric Blood & Cancer, 67(4), e28061. https://doi.org/10.1002/pbc.28061
Calandrini, C., Schutgens, F., Oka, R., Margaritis, T., Candelli, T., Mathijsen, L., Ammerlaan, C., van Ineveld, R. L., Derakhshan, S., de Haan, S., Dolman, E., Lijnzaad, P., Custers, L., Begthel, H., Kerstens, H. H. D., Visser, L. L., Rookmaaker, M., Verhaar, M., Tytgat, G. A. M., ... Drost, J. (2020). An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nature Communications, 11(1), 1310. https://doi.org/10.1038/s41467-020-15155-6
Schubert, N. A., Lowery, C. D., Bergthold, G., Koster, J., Eleveld, T. F., Rodríguez, A., Jones, D. T. W., Vassal, G., Stancato, L. F., Pfister, S. M., Caron, H. N., & Molenaar, J. J. (2020). Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers. European Journal of Cancer, 130, 168-181. https://doi.org/10.1016/j.ejca.2020.01.027
Wander, P., Cheung, L. C., Pinhanҫos, S. S., Jones, L., Kerstjens, M., Arentsen-Peters, S. T. C. J. M., Singh, S., Chua, G-A., Castro, P. G., Schneider, P., Dolman, M. E. M., Koopmans, B., Molenaar, J. J., Pieters, R., Zwaan, C. M., Kotecha, R. S., & Stam, R. W. (2020). Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia, 34(11), 2898-2902. https://doi.org/10.1038/s41375-020-0895-9
Moreno, L., Barone, G., DuBois, S. G., Molenaar, J., Fischer, M., Schulte, J., Eggert, A., Schleiermacher, G., Speleman, F., Chesler, L., Geoerger, B., Hogarty, M. D., Irwin, M. S., Bird, N., Blanchard, G. B., Buckland, S., Caron, H., Davis, S., De Wilde, B., ... Pearson, A. D. J. (2020). Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European Journal of Cancer, 136, 52-68. https://doi.org/10.1016/j.ejca.2020.05.010
George, S. L., Lorenzi, F., King, D., Hartlieb, S., Campbell, J., Pemberton, H., Toprak, U. H., Barker, K., Tall, J., da Costa, B. M., van den Boogaard, M. L., Dolman, M. E. M., Molenaar, J. J., Bryant, H. E., Westermann, F., Lord, C. J., & Chesler, L. (2020). Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma. EBioMedicine, 59, 102971. https://doi.org/10.1016/j.ebiom.2020.102971
Manzella, G., Schreck, L. D., Breunis, W. B., Molenaar, J., Merks, H., Barr, F. G., Sun, W., Römmele, M., Zhang, L., Tchinda, J., Ngo, Q. A., Bode, P., Delattre, O., Surdez, D., Rekhi, B., Niggli, F. K., Schäfer, B. W., & Wachtel, M. (2020). Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity. Nature Communications, 11(1), 4629. https://doi.org/10.1038/s41467-020-18388-7
Poon, E., Liang, T., Jamin, Y., Walz, S., Kwok, C., Hakkert, A., Barker, K., Urban, Z., Thway, K., Zeid, R., Hallsworth, A., Box, G., Ebus, M. E., Licciardello, M. P., Sbirkov, Y., Lazaro, G., Calton, E., Costa, B. M., Valenti, M., ... Chesler, L. (2020). Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. Journal of Clinical Investigation, 130(11), 5875-5892. https://doi.org/10.1172/JCI134132
Wellens, L. M., Deken, M. M., Sier, C. F. M., Johnson, H. R., de la Jara Ortiz, F., Bhairosingh, S. S., Houvast, R. D., Kholosy, W. M., Baart, V. M., Pieters, A. M. M. J., de Krijger, R. R., Molenaar, J. J., Wehrens, E. J., Dekkers, J. F., Wijnen, M. H. W. A., Vahrmeijer, A. L., & Rios, A. C. (2020). Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma. Scientific Reports, 10(1), 17667. https://doi.org/10.1038/s41598-020-74464-4
2019
Scholarly publications
Claeys, S., Denecker, G., Durinck, K., Decaesteker, B., Mus, L. M., Loontiens, S., Vanhauwaert, S., Althoff, K., Wigerup, C., Bexell, D., Dolman, E., Henrich, K-O., Wehrmann, L., Westerhout, E. M., Demoulin, J-B., Kumps, C., Van Maerken, T., Laureys, G., Van Neste, C., ... Speleman, F. (2019). ALK positively regulates MYCN activity through repression of HBP1 expression. Oncogene, 38(15), 2690-2705. https://doi.org/10.1038/s41388-018-0595-3
Herold, S., Kalb, J., Büchel, G., Ade, C. P., Baluapuri, A., Xu, J., Koster, J., Solvie, D., Carstensen, A., Klotz, C., Rodewald, S., Schülein-Völk, C., Dobbelstein, M., Wolf, E., Molenaar, J., Versteeg, R., Walz, S., & Eilers, M. (2019). Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase. Nature, 567(7749), 545-549. https://doi.org/10.1038/s41586-019-1030-9
Jones, D. T. W., Banito, A., Grünewald, T. G. P., Haber, M., Jäger, N., Kool, M., Milde, T., Molenaar, J. J., Nabbi, A., Pugh, T. J., Schleiermacher, G., Smith, M. A., Westermann, F., & Pfister, S. M. (2019). Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. Nature Reviews Cancer, 19(8), 420-438. https://doi.org/10.1038/s41568-019-0169-x
2018
Scholarly publications
ICGC PedBrain-Seq Project (2018). The landscape of genomic alterations across childhood cancers. Nature, 555(7696), 321-327. https://doi.org/10.1038/nature25480
ICGC PedBrain-Seq Project (2018). Author Correction: The landscape of genomic alterations across childhood cancers. Nature, 559(7714), E10. https://doi.org/10.1038/s41586-018-0167-2
Eleveld, T. F., Schild, L., Koster, J., Zwijnenburg, D. A., Alles, L. K., Ebus, M. E., Volckmann, R., Tijtgat, G. A., van Sluis, P., Versteeg, R., & Molenaar, J. J. (2018). RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma. Cancer Research, 78(21), 6297-6307. https://doi.org/10.1158/0008-5472.CAN-18-1045
Decaesteker, B., Denecker, G., Van Neste, C., Dolman, E. M., Van Loocke, W., Gartlgruber, M., Nunes, C., De Vloed, F., Depuydt, P., Verboom, K., Rombaut, D., Loontiens, S., De Wyn, J., Kholosy, W. M., Koopmans, B., Essing, A. H. W., Herrmann, C., Dreidax, D., Durinck, K., ... Speleman, F. (2018). TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. Nature Communications, 9(1), 4866. https://doi.org/10.1038/s41467-018-06699-9
2017
Scholarly publications
Bate-Eya, L. T., Gierman, H. J., Ebus, M. E., Koster, J., Caron, H. N., Versteeg, R., Dolman, M. E. M., & Molenaar, J. J. (2017). Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. European Journal of Cancer, 75, 63-72. https://doi.org/10.1016/j.ejca.2016.12.019
Walsh, M. F., Chang, V. Y., Kohlmann, W. K., Scott, H. S., Cunniff, C., Bourdeaut, F., Molenaar, J. J., Porter, C. C., Sandlund, J. T., Plon, S. E., Wang, L. L., & Savage, S. A. (2017). Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders. Clinical Cancer Research, 23(11), e23-e31. https://doi.org/10.1158/1078-0432.CCR-17-0465
Moreno, L., Caron, H., Geoerger, B., Eggert, A., Schleiermacher, G., Brock, P., Valteau-Couanet, D., Chesler, L., Schulte, J. H., De Preter, K., Molenaar, J., Schramm, A., Eilers, M., Van Maerken, T., Johnsen, J. I., Garrett, M., George, S. L., Tweddle, D. A., Kogner, P., ... Pearson, A. D. (2017). Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 12(8), 801-811. https://doi.org/10.1080/17460441.2017.1340269
Foulkes, W. D., Kamihara, J., Evans, D. G. R., Brugières, L., Bourdeaut, F., Molenaar, J. J., Walsh, M. F., Brodeur, G. M., & Diller, L. (2017). Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. Clinical Cancer Research, 23(12), e62-e67. https://doi.org/10.1158/1078-0432.CCR-17-0595
van Groningen, T., Koster, J., Valentijn, L. J., Zwijnenburg, D. A., Akogul, N., Hasselt, N. E., Broekmans, M., Haneveld, F., Nowakowska, N. E., Bras, J., van Noesel, C. J. M., Jongejan, A., van Kampen, A. H., Koster, L., Baas, F., van Dijk-Kerkhoven, L., Huizer-Smit, M., Lecca, M. C., Chan, A., ... Versteeg, R. (2017). Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nature Genetics, 49(8), 1261-1266. https://doi.org/10.1038/ng.3899
Kamihara, J., Bourdeaut, F., Foulkes, W. D., Molenaar, J. J., Mossé, Y. P., Nakagawara, A., Parareda, A., Scollon, S. R., Schneider, K. W., Skalet, A. H., States, L. J., Walsh, M. F., Diller, L. R., & Brodeur, G. M. (2017). Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clinical Cancer Research, 23(13), e98-e106. https://doi.org/10.1158/1078-0432.CCR-17-0652
Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium (2017). From class waivers to precision medicine in paediatric oncology. The Lancet Oncology, 18(7), e394-e404. https://doi.org/10.1016/S1470-2045(17)30442-4
Moreno-Smith, M., Lakoma, A., Chen, Z., Tao, L., Scorsone, K. A., Schild, L., Aviles-Padilla, K., Nikzad, R., Zhang, Y., Chakraborty, R., Molenaar, J. J., Vasudevan, S. A., Sheehan, V., Kim, E. S., Paust, S., Shohet, J. M., & Barbieri, E. (2017). p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. Clinical Cancer Research, 23(21), 6629-6639. https://doi.org/10.1158/1078-0432.CCR-17-0668
2016
Scholarly publications
within the ITCC Biology and Preclinical Evaluation Committee (2016). Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies. Anticancer Research, 36(2), 599-609.
Bate-Eya, L. T., den Hartog, I. J. M., van der Ploeg, I., Schild, L., Koster, J., Santo, E. E., Westerhout, E. M., Versteeg, R., Caron, H. N., Molenaar, J. J., & Dolman, M. E. M. (2016). High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. Oncotarget, 7(19), 27946-58. https://doi.org/10.18632/oncotarget.8547
Dorneburg, C., Goß, A. V., Fischer, M., Roels, F., Barth, T. F. E., Berthold, F., Kappler, R., Oswald, F., Siveke, J. T., Molenaar, J. J., Debatin, K-M., & Beltinger, C. (2016). γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets. Oncotarget, 7(39), 62799-62813. https://doi.org/10.18632/oncotarget.11715
Astola, L., Stigter, H., Gomez Roldan, M. V., van Eeuwijk, F., Hall, R. D., Groenenboom, M., & Molenaar, J. J. (2016). Parameter estimation in tree graph metabolic networks. PeerJ, 4, e2417. https://doi.org/10.7717/peerj.2417
2015
Scholarly publications
Althoff, K., Lindner, S., Odersky, A., Mestdagh, P., Beckers, A., Karczewski, S., Molenaar, J. J., Bohrer, A., Knauer, S., Speleman, F., Epple, M., Kozlova, D., Yoon, S., Baek, K., Vandesompele, J., Eggert, A., Schramm, A., & Schulte, J. H. (2015). miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. International Journal of Cancer, 136(6), 1308-20. https://doi.org/10.1002/ijc.29091
van Wezel, E. M., Zwijnenburg, D., Zappeij-Kannegieter, L., Bus, E., van Noesel, M. M., Molenaar, J. J., Versteeg, R., Fiocco, M., Caron, H. N., van der Schoot, C. E., Koster, J., & Tytgat, G. A. M. (2015). Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma. Journal of Molecular Diagnostics, 17(1), 43-52. https://doi.org/10.1016/j.jmoldx.2014.09.005
Ariës, I. M., van den Dungen, R. E., Koudijs, M. J., Cuppen, E., Voest, E., Molenaar, J. J., Caron, H. N., Pieters, R., & den Boer, M. L. (2015). Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance. Haematologica, 100(4), e132-6. https://doi.org/10.3324/haematol.2014.112995
Mandriota, S. J., Valentijn, L. J., Lesne, L., Betts, D. R., Marino, D., Boudal-Khoshbeen, M., London, W. B., Rougemont, A-L., Attiyeh, E. F., Maris, J. M., Hogarty, M. D., Koster, J., Molenaar, J. J., Versteeg, R., Ansari, M., & Gumy-Pause, F. (2015). Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget, 6(21), 18558-76. https://doi.org/10.18632/oncotarget.4061
Eleveld, T. F., Oldridge, D. A., Bernard, V., Koster, J., Colmet Daage, L., Diskin, S. J., Schild, L., Bentahar, N. B., Bellini, A., Chicard, M., Lapouble, E., Combaret, V., Legoix-Né, P., Michon, J., Pugh, T. J., Hart, L. S., Rader, J., Attiyeh, E. F., Wei, J. S., ... Maris, J. M. (2015). Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 47(8), 864-71. https://doi.org/10.1038/ng.3333
Beckers, A., Van Peer, G., Carter, D. R., Gartlgruber, M., Herrmann, C., Agarwal, S., Helsmoortel, H. H., Althoff, K., Molenaar, J. J., Cheung, B. B., Schulte, J. H., Benoit, Y., Shohet, J. M., Westermann, F., Marshall, G. M., Vandesompele, J., De Preter, K., & Speleman, F. (2015). MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma. Cancer Letters, 366(1), 123-32. https://doi.org/10.1016/j.canlet.2015.06.015
Dolman, M. E. M., Poon, E., Ebus, M. E., den Hartog, I. J. M., van Noesel, C. J. M., Jamin, Y., Hallsworth, A., Robinson, S. P., Petrie, K., Sparidans, R. W., Kok, R. J., Versteeg, R., Caron, H. N., Chesler, L., & Molenaar, J. J. (2015). Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical Cancer Research, 21(22), 5100-9. https://doi.org/10.1158/1078-0432.CCR-15-0313
Spel, L., Boelens, J-J., van der Steen, D. M., Blokland, N. J. G., van Noesel, M. M., Molenaar, J. J., Heemskerk, M. H. M., Boes, M., & Nierkens, S. (2015). Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget, 6(34), 35770-81. https://doi.org/10.18632/oncotarget.5657
Valentijn, L. J., Koster, J., Zwijnenburg, D. A., Hasselt, N. E., van Sluis, P., Volckmann, R., van Noesel, M. M., George, R. E., Tytgat, G. A. M., Molenaar, J. J., & Versteeg, R. (2015). TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nature Genetics, 47(12), 1411-4. https://doi.org/10.1038/ng.3438
Dolman, M. E. M., van der Ploeg, I., Koster, J., Bate-Eya, L. T., Versteeg, R., Caron, H. N., & Molenaar, J. J. (2015). DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells. PLoS One, 10(12), e0145744. https://doi.org/10.1371/journal.pone.0145744
2014
Scholarly publications
Dolman, M. E. M., den Hartog, I. J. M., Molenaar, J. J., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2014). Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis, 88, 216-20. https://doi.org/10.1016/j.jpba.2013.08.051
Kloosterman, W. P., Koster, J., & Molenaar, J. J. (2014). Prevalence and clinical implications of chromothripsis in cancer genomes. Current Opinion in Oncology, 26(1), 64-72. https://doi.org/10.1097/CCO.0000000000000038
Bate-Eya, L. T., Ebus, M. E., Koster, J., den Hartog, I. J. M., Zwijnenburg, D. A., Schild, L., van der Ploeg, I., Dolman, M. E. M., Caron, H. N., Versteeg, R., & Molenaar, J. J. (2014). Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. European Journal of Cancer, 50(3), 628-37. https://doi.org/10.1016/j.ejca.2013.11.015
Dolman, M. E. M., den Hartog, I. J. M., Molenaar, J. J., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2014). Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis, 92, 144-8. https://doi.org/10.1016/j.jpba.2014.01.011
2013
Scholarly publications
Schulte, J. H., Lindner, S., Bohrer, A., Maurer, J., De Preter, K., Lefever, S., Heukamp, L., Schulte, S., Molenaar, J., Versteeg, R., Thor, T., Künkele, A., Vandesompele, J., Speleman, F., Schorle, H., Eggert, A., & Schramm, A. (2013). MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene, 32(8), 1059-65. https://doi.org/10.1038/onc.2012.106
2012
Scholarly publications
Santo, E. E., Ebus, M. E., Koster, J., Schulte, J. H., Lakeman, A., van Sluis, P., Vermeulen, J., Gisselsson, D., Øra, I., Lindner, S., Buckley, P. G., Stallings, R. L., Vandesompele, J., Eggert, A., Caron, H. N., Versteeg, R., & Molenaar, J. J. (2012). Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene, 31(12), 1571-81. https://doi.org/10.1038/onc.2011.344
Molenaar, J. J., Koster, J., Ebus, M. E., van Sluis, P., Westerhout, E. M., de Preter, K., Gisselsson, D., Øra, I., Speleman, F., Caron, H. N., & Versteeg, R. (2012). Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes and Cancer, 51(1), 10-9. https://doi.org/10.1002/gcc.20926
Lamers, F., Schild, L., Koster, J., Versteeg, R., Caron, H. N., & Molenaar, J. J. (2012). Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. European Journal of Cancer, 48(5), 763-71. https://doi.org/10.1016/j.ejca.2011.10.012
Rausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., Pfaff, E., Tica, J., Wang, Q., Massimi, L., Witt, H., Bender, S., Pleier, S., Cin, H., Hawkins, C., ... Korbel, J. O. (2012). Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell, 148(1-2), 59-71. https://doi.org/10.1016/j.cell.2011.12.013
Lamers, F., Schild, L., den Hartog, I. J. M., Ebus, M. E., Westerhout, E. M., Ora, I., Koster, J., Versteeg, R., Caron, H. N., & Molenaar, J. J. (2012). Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth. European Journal of Cancer, 48(16), 3093-103. https://doi.org/10.1016/j.ejca.2012.01.037
Molenaar, J. J., Koster, J., Zwijnenburg, D. A., van Sluis, P., Valentijn, L. J., van der Ploeg, I., Hamdi, M., van Nes, J., Westerman, B. A., van Arkel, J., Ebus, M. E., Haneveld, F., Lakeman, A., Schild, L., Molenaar, P., Stroeken, P., van Noesel, M. M., Ora, I., Santo, E. E., ... Versteeg, R. (2012). Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature, 483(7391), 589-93. https://doi.org/10.1038/nature10910
Lamers, F., Schild, L., Koster, J., Speleman, F., Øra, I., Westerhout, E. M., van Sluis, P., Versteeg, R., Caron, H. N., & Molenaar, J. J. (2012). Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. BMC Cancer, 12, 285. https://doi.org/10.1186/1471-2407-12-285
Molenaar, J. J., Domingo-Fernández, R., Ebus, M. E., Lindner, S., Koster, J., Drabek, K., Mestdagh, P., van Sluis, P., Valentijn, L. J., van Nes, J., Broekmans, M., Haneveld, F., Volckmann, R., Bray, I., Heukamp, L., Sprüssel, A., Thor, T., Kieckbusch, K., Klein-Hitpass, L., ... Schulte, J. H. (2012). LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nature Genetics, 44(11), 1199-206. https://doi.org/10.1038/ng.2436
Valentijn, L. J., Koster, J., Haneveld, F., Aissa, R. A., van Sluis, P., Broekmans, M. E. C., Molenaar, J. J., van Nes, J., & Versteeg, R. (2012). Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proceedings of the National Academy of Sciences of the United States of America, 109(47), 19190-5. https://doi.org/10.1073/pnas.1208215109
2011
Scholarly publications
Murphy, D. M., Buckley, P. G., Bryan, K., Watters, K. M., Koster, J., van Sluis, P., Molenaar, J., Versteeg, R., & Stallings, R. L. (2011). Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Molecular Carcinogenesis, 50(6), 403-11. https://doi.org/10.1002/mc.20722
Lamers, F., van der Ploeg, I., Schild, L., Ebus, M. E., Koster, J., Hansen, B. R., Koch, T., Versteeg, R., Caron, H. N., & Molenaar, J. J. (2011). Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocrine-Related Cancer, 18(6), 657-68. https://doi.org/10.1530/ERC-11-0207
Verissimo, C. S., Molenaar, J. J., Fitzsimons, C. P., & Vreugdenhil, E. (2011). Neuroblastoma therapy: what is in the pipeline? Endocrine-Related Cancer, 18(6), R213-31. https://doi.org/10.1530/ERC-11-0251
De Preter, K., Mestdagh, P., Vermeulen, J., Zeka, F., Naranjo, A., Bray, I., Castel, V., Chen, C., Drozynska, E., Eggert, A., Hogarty, M. D., Izycka-Swieszewska, E., London, W. B., Noguera, R., Piqueras, M., Bryan, K., Schowe, B., van Sluis, P., Molenaar, J. J., ... Vandesompele, J. (2011). miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clinical Cancer Research, 17(24), 7684-92. https://doi.org/10.1158/1078-0432.CCR-11-0610
2010
Scholarly publications
Molenaar, J. J., Ebus, M. E., Koster, J., Santo, E., Geerts, D., Versteeg, R., & Caron, H. N. (2010). Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells. Oncogene, 29(18), 2739-45. https://doi.org/10.1038/onc.2010.21
Verissimo, C. S., Molenaar, J. J., Meerman, J., Puigvert, J. C., Lamers, F., Koster, J., Danen, E. H. J., van de Water, B., Versteeg, R., Fitzsimons, C. P., & Vreugdenhil, E. (2010). Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells. Endocrine-Related Cancer, 17(2), 399-414. https://doi.org/10.1677/ERC-09-0301
Fardin, P., Barla, A., Mosci, S., Rosasco, L., Verri, A., Versteeg, R., Caron, H. N., Molenaar, J. J., Ora, I., Eva, A., Puppo, M., & Varesio, L. (2010). A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Molecular Cancer, 9, 185. https://doi.org/10.1186/1476-4598-9-185
2009
Scholarly publications
Molenaar, J. J., Ebus, M. E., Geerts, D., Koster, J., Lamers, F., Valentijn, L. J., Westerhout, E. M., Versteeg, R., & Caron, H. N. (2009). Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 106(31), 12968-73. https://doi.org/10.1073/pnas.0901418106
2008
Scholarly publications
Molenaar, J. J., Ebus, M. E., Koster, J., van Sluis, P., van Noesel, C. J. M., Versteeg, R., & Caron, H. N. (2008). Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Research, 68(8), 2599-609. https://doi.org/10.1158/0008-5472.CAN-07-5032
2007
Scholarly publications
Michels, E., Vandesompele, J., De Preter, K., Hoebeeck, J., Vermeulen, J., Schramm, A., Molenaar, J. J., Menten, B., Marques, B., Stallings, R. L., Combaret, V., Devalck, C., De Paepe, A., Versteeg, R., Eggert, A., Laureys, G., Van Roy, N., & Speleman, F. (2007). ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes and Cancer, 46(12), 1098-108. https://doi.org/10.1002/gcc.20496
2005
Scholarly publications
Onland, W., Molenaar, J. J., Leguit, R. J., van Nierop, J. C., Noorduyn, L. A., van Rijn, R. R., & Geukers, V. G. M. (2005). Pulmonary interstitial glycogenosis in identical twins. Pediatric Pulmonology, 40(4), 362-6. https://doi.org/10.1002/ppul.20255
2003
Scholarly publications
Molenaar, J. J., van Sluis, P., Boon, K., Versteeg, R., & Caron, H. N. (2003). Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes and Cancer, 36(3), 242-9. https://doi.org/10.1002/gcc.10166
1998
Scholarly publications
Molenaar, J. J., Gérard, B., Chambon-Pautas, C., Cavé, H., Duval, M., Vilmer, E., & Grandchamp, B. (1998). Microsatellite instability and frameshift mutations in BAX and transforming growth factor-beta RII genes are very uncommon in acute lymphoblastic leukemia in vivo but not in cell lines. Blood, 92(1), 230-3.
1993
Scholarly publications
Bogers, A. J., Hazebroek, F. W., Molenaar, J., & Bos, E. (1993). Surgical treatment of congenital bronchopulmonary disease in children. European Journal of Cardio-thoracic Surgery, 7(3), 117-20. https://doi.org/10.1016/1010-7940(93)90032-7